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Abstract 
Antigenic domains are defined to contain a limited number of neighboring epitopes recognized by 
antibodies (Abs) but their molecular relationship remains rather elusive. We thoroughly analyzed the 
antigenic surface of the most important pregnancy and tumor marker human chorionic gonadotropin 
(hCG), a cystine knot (ck) growth factor, and set antigenic domains and epitopes in molecular 
relationships to each other. Antigenic domains on hCG, its free hCGα and hCGβ subunits are 
dependent on appropriate inherent molecular features such as molecular accessibility and protrusion 
indices that determine bulging structures accessible to Abs. The banana-shaped intact hCG 
comprises ~7,500 Å2 of antigenic surface with minimally five antigenic domains that encompass a 
continuum of overlapping non-linear composite epitopes, not taking into account the C-terminal 
peptide extension of hCGβ (hCGβCTP). Epitopes within an antigenic domain are defined by specific 
Abs, that bury nearly 1,000 Å2 of surface accessible area on the antigen and recognize a few up to 15 
amino acid (aa) residues, whereby between 2 and 5 of these provide the essential binding energy. 
Variability in Ab binding modes to the contact aa residues are responsible for the variation in affinity 
and intra- and inter-species specificity, e.g. cross-reactions with luteinizing hormone (LH). Each 
genetically distinct fragment antigen binding (Fab) defines its own epitope. Consequently, recognition 
of the same epitope by different Abs is only possible in cases of genetically identical sequences of its 
binding sites. Due to combinatorial V(D)J gene segment variability of heavy and light chains, Abs 
defining numerous epitopes within an antigenic domain can be generated by different individuals and 
species. Far more than one hundred Abs against the immune-dominant antigenic domains of either 
subunit correspond to both ends of the hCG-molecule, the tips of peptide loops one and three (Ł1+3) 
protruding from the central ck, encompassing hCGβŁ1+3 corresponding to aa 20-25+64+68-81 and 
hCGαŁ1 aa 13-22 (Pro16, Phe17, Phe18) plus hCGαŁ3 (Met71, Phe74), respectively, have been 
identified in two “ISOBM Tissue Differentiation-7 Workshops on hCG and Related Molecules” and by 
other studies. These Abs recognize distinct but overlapping epitopes with slightly different specificity 
profiles and affinities. Heterodimeric-specific epitopes involve neighboring αŁ1 plus βŁ2 (hCGβ44/45 
and 47/48). Diagnostically important Abs recognize the middle of the molecule, the ck (aa Arg10, 
Arg60 and possibly Gln89) and the linear hCGβCTP “tail” (aa 135-145; Asp139, Pro144, Gln145), 
respectively.  Identification of antigenic domains and of specific epitopes is essential for harmonization 
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of Abs in methods that are used for reliable and robust hCG measurements for the management of 
pregnancy, pregnancy-related disease and tumors.  
 
1. hCG and variants are important clinical pregnancy and tumor markers 
The dimeric glycoprotein hormone (GPH) human chorionic gonadotropin (hCG) is synthesized by 
the placental trophoblast and controls pregnancy by stimulating progesterone production in the corpus 
luteum. hCG and its variants are also secreted by hydaditiform mole, a benign gestational 
trophoblastic disease, as well as a variety of tumors in particular choriocarcinoma, testicular cancer 
and bladder cancer. Thus, they serve as reliable diagnostic markers for the detection of pregnancy, 
the management of pregnancy-related disease and trophoblastic and non-trophoblastic tumors [1-4]. 
In its strict sense hCG is defined as the biologically active heterodimeric hormone but hCG is also 
used as an umbrella term for a plethora of genomic, posttranslational and metabolized protein 
backbone variants that result from modifications like nicking, truncation, homo-dimerization, oxidation 
and variable glycosylation, thus does not denote a unique chemical entity. It occurs in highly varying 
concentrations and variant formulations in body fluids like serum, urine, seminal plasma, extra 
embryonic coelomic fluid and liquor (for reviews see [1-3, 5].  
The “International Federation of Clinical Chemistry (IFCC) Working Group (WG) on 
Standardization of hCG Measurements” identified and defined six protein backbone variants of 
potential clinical interest: the bioactive αβ-heterodimer, hCG, its free subunits hCGα and hCGβ, hCGβ 
core fragment (hCGβcf) and peptidase nicked hCG (hCGn) and hCGβ (hCGβn).  This WG established 
respective new 1st International Reference Reagents (IRR) and the 5th International Standard (IS) for 
hCG calibrated in SI units (molar units). These are meant to be used for the characterization of 
diagnostic antibodies (Abs) and methods for hCG measurement as well as its calibrations [6-10] 
(Figure 1, Table 1). 
 
2. hCG, a cystine knot growth factor 
hCG and the three pituitary-derived GPHs human (h) luteinizing hormone (hLH), follicle 
stimulating hormone (hFSH) and thyroid stimulating hormone (hTSH) are cystine knot (ck) growth 
factors composed of two non-covalently linked α- and β-subunits. The GPHs, in particular hCG and 
hLH that share approximately >85% structural homology in their β-subunits (hCGβ vs. hLHβ) and bind 
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to the same receptor, genetically, biochemically and in their antigenic appearance are closely related. 
Their prominent structural feature is a central ck in either subunit whereby two disulfide bonds link two 
anti-parallel β-strands forming a ring that is axially crossed by a third disulfide bond. From this knot 
three peptide loops protrude, αŁ1 to αŁ3 and βŁ1 and βŁ3, respectively, whereby the two twisted 
neighboring loops Ł1 and Ł3 of each subunit are diametrically opposed by loop Ł2 [11].  
Symbol WHO code Content/ampoule Molecular definition MWb) 
hCGc) 3rd IS 75/537 70µg or 650 IU  
intact αβ heterodimer, 
bioactive a) 
 
hCGc) 4th IS 75/589 70µg or 650 IU  
hCGd) 5th IS 07/364 0.39 nmol or 179 IU  35,336 – 37,338 
hCGd) 1st IRR 99/688 1.88 nmol 
     
hCGn 1st IRR 99/642 0.78 nmol hCG nicked at hCGβ44-48 a)  
hCGβ 1st IRR 99/650 0.84 nmol hCGβ subunit (hCGβ1-145) a) 22,336 – 23,667 
hCGn  1st IRR 99/692 0.88 nmol hCGβ nicked at aa 44-48 a)  
hCGβcf 1st IRR 99/708 0.33 nmol hCGβcore fragment;  
hCGβ6-40 linked to β55-92 a) 
 
hCGα 1st IRR 99/720 1.02 nmol hCGα subunit (hCGα1-92) a) 13,000 – 13,671 
     
hCGβ 1st IRP 75/551 70µg; 70 IU hCGβ subunit (hCGβ1-145)  
hCGα 1st IRP 75/569 70µg; 70 IU hCGα subunit (hCGα1-92)  
     
hCGβCTP e)  hCGβ C-terminal peptide,  
(aa hCGβ109/114-145) 
 
-CTPhCG e)  hCG missing most of the CTP  
(aa β121-145) 
 
-
CTPhCG 
e)
  hCGβ missing most of the CTP 
(aa hCGβ121-145) 
 
hCGav e)  acidic variant of hCG,  
synonymic to hhCG [12] 
 
hhCG e)  hyperglycosylated hCG  
Table 1, hCG and hCG-related variants: Nomenclature, International Standards (IS), 
International Reference Reagents (IRR) and International Reference Preparations (IRP) 
a) Abbreviations and definitions for hCG and hCG-derived molecules as put forward by the IFCC 
Working Group for Standardization of hCG [6, 7]. 
b)
 determined by RP HPLC-ESI-MS; non-trypsinized i.e. native frozen concentrate [13] 
c)
 bioactivity/mass = 9,200 IU/mg 
d)
 bioactivity/mass = 12,240 IU/mg determined by immunoassay 
e)
 no standard available 
aa…amino acids 
 
hCGβ carries a unique carboxyl-terminal peptide “tail” (hCGβCTP, aa β113-145) which structurally 
discerns hCGβ from hLHβ. It has evolved by a mutational frameshift caused by a base pair deletion at 
aa β113 and loss of the first stop codon in the ancestral hLHβ gene leading to a read-through event 
and incorporation of a previously untranslated peptide sequence into the open reading frame [14]. It is 
not involved in receptor-binding and biological activity [15] but significantly prolongs metabolic half-life 
in serum [16, 17]. This hCGβ and hCG-specific sequence is of great interest for the design of highly 
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specific immunoassays, fertility regulating and anti-hCG cancer vaccines as well as long-acting 
erythropoietins [7, 15, 17, 18]. 
 
3. Glycosylation and microheterogeneity 
Glycosylation of hCG is required for correct intracellular folding and assembly of subunits, 
secretion, receptor activation and metabolic half-life in circulation [19]. Both subunits are heavily 
glycosylated so that approximately one third of hCG’s molecular mass consists of carbohydrates. 
hCGα carries two branched N-linked carbohydrate antennae at Asn52 and 78, whereas hCGβ 
contains two at Asn13 and 30 plus four branches linked by O-glycosylation to Ser121,127,132 and 
138. Molecular microheterogeneity is caused by variability in carbohydrate branching (mono-, di- or tri-
antennae) and terminal sialylation (Figure 1). 
The composition of hCG protein backbone variants and glycosylation isoforms show stark 
absolute and relative dynamics in concentrations with progression of pregnancy and tumor type [2, 20-
23]. While it seems that more intensely glycosylated hCG isoforms dominate at the beginning of 
pregnancy a change in median molecular charge reflecting less glycosylated hCG isoforms occurs 
around week 13 of gestation in urine and serum [24, 25]. The major urinary hCG variant after 3 weeks 
of gestation until parturation is hCGβcf (Figure 1) that is largely deglycosylated and only contains 
rudimentary N-linked mannose cores [26]. It is generated primarily in the kidney [27].  
In addition there do exist other less well defined variants such as the acidic variant of hCG 
(avhCG), including hyperglycosylated hCG (hhCG), observed in serum and urine of patients 
presenting with trophoblastic disease [12, 24, 30], -CTPhCG and -CTPhCGβ both truncated after amino 
acid hCGβ117 [12, 31-33], the clipped carboxyl-terminal peptide of hCG (hCGβCTP) encompassing 
approx. amino acids hCGβ117-145, hCGββ homodimers [34] and hCGαα homodimers that are 
observed in sera of testicular cancer patients [12], seminal plasma [35] and choriocarcinoma cells [19]. 
Variability in glycosylation is mirrored by a broader range of molecular masses [36] that, as 
determined by ion pair reversed phase (RP) HPLC-ESI-MS, ranged between 13,000 and 13,671 for 
the non-trypsinized concentrate of the 1st IRR for hCGα (99/720) and 22,336 to 23,667 for the 1st IRR 
for hCGβ (99/650). As both subunits were derived by dissociation of the purified starting material of 
the 1st IRR 99/688 and the 5th IS 07/364 for hCG, the calculated mass for intact pregnancy hCG 
ranges from 35,336 to 37,338 [13, 37] (Table 1). Despite the high number of potential glycosylation 
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variants, greater than 3,000 glycosylation isoforms for hCGα and  13,800 for hCGβ, only 14 major 
variants for hCGα (1st IRR 99/720) and 12 for hCGβ (1st IRR 99/650) have been observed [13]. 
 
4. Why are hCG epitopes important? 
For reliable patient management diagnostic “hCG” results of measurements in pregnancy and 
disease should be comparable between Ab-based sandwich methods of different manufacturers and 
laboratories. The most important parameters to achieve robust and reliable “hCG” results are:  
 
i. adequate universally adopted commutable international standards (IS) and international 
reference reagents (IRR) calibrated in molar units 
ii. an unambiguous nomenclature of and clinical consent on the hCG variants and isoforms 
being measured and finally 
iii. the harmonization of the diagnostic Abs applied in sandwich assays regarding recognition of 
epitopes and consequently specificity profiles [4, 7, 38]. 
 
In particular harmonization of epitopes in commercial assays has generally been neglected until 
now, not only for hCG but also for other analytes, and variability in method design. Non-standardized 
Abs’ specificities still leads to differences in results either due to selective over-specificity in variant 
recognition, undesired cross-reactivity or interference of non-measured metabolic variants like hCGβcf 
that are only detected by one of the two Abs in sandwich assays (hook-effect) [4, 38-41]. Thus 
identification and harmonization of epitopes recognized by diagnostic Abs will in future improve 
method comparability and consequently patient management [38].  
 
5. hCG epitope identification 
Unfortunately a comprehensive array of anti-hCG-antibody:antigen complexes with accurate data 
on the molecular location of recognized epitopes is not available, due in no small part to the difficulty 
of crystallizing hCG and other glycoprotein hormones. Therefore a combined approach to assign hCG 
epitopes to diagnostically relevant antibodies was developed and applied by  
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i. determining Ab specificity profiles by quantitative intra-molecular, intra-species and inter-
species specificity characterization by separately testing mAbs in question with hCG, hCG 
related variants (non-assembled hCG subunits, hCGβcf, deglycosylated hCG, asialo-hCG, 
avhCG, etc.), hLH, hLHβ, LH and CG of other species and free subunits thereof or synthetic 
hCG peptides (soluble and solid-phase), and consequently grouping of mAbs according to the 
main specificities (α-, β- and c-mAbs) and preliminarily to epitope recognition (for reviews see 
[41-43]. 
ii. testing for mutual exclusion or binding of hCG and/or hCG related molecules in a chessboard-
like fashion by pairs of mAbs in sandwich type assays for discerning epitopes and the 
elucidation of the spatial relationship of epitopes [44, 45],  
iii. defining antigenic domains by schematic grouping of mAbs according to their specific reaction 
profiles [44-46] and finally  
iv. pin pointing molecular localization of epitopes recognized by representative mAbs from each 
group by mutational analysis of hCGβ [47, 48] based on the three-dimensional X-ray structure 
of hCG [11]. Single selected amino acids were mutated by PCR and tested for effects on mAb 
binding whereby special care was taken not to disturb the overall molecular configuration of 
hCGβ as evaluated by molecular modelling using the programs O [49] and Sculpt [50] with the 
crystallographic coordinates of hCG [11].  
 
On the basis of data generated with this methodology epitope maps were designed for hCG, 
hCGβ, hCGβcf and hCGα (Figure 2) and characteristic reference Abs for each epitope defined [7, 42, 
43]. In two “ISOBM Tissue Differentiation (TD)-7 Workshops (TD-7 WSs) on hCG and Related 
Molecules” 96 Abs of 17 manufacturers and laboratories were epitope typed by cross-comparison to 
the reference Abs with previously determined molecular epitope recognition and their specificity 
profiles determined [7, 41]. 
 
6. Epitopes and antigenic domains 
Antigenic domains and epitopes contained therein are dependent on two features: 
i. appropriate inherent molecular structures of the antigen that are characterized by molecular 
accessibility and protrusion indices [51], and  
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ii. complementary Abs recognizing these structures [41, 52]. Thus, epitopes are molecular 
structures that acquire identity by complementary Abs [41, 53]. An epitope is ultimately 
defined by the Ab’s complementarity determining regions (CDRs), the antigen binding site, 
and its contact points within the inherent molecular structure of an antigenic domain 
providing a functional epitope [54].  
 
Epitopes within antigenic domains are determined by the complementary Abs’ paratopes binding 
to slightly different sets of aa residues but covering more or less the same molecular region by its 
Fabs. Classification of Abs according to their recognition of certain antigenic domains is possible but 
definitions of epitopes are just approximations as most monoclonal (m) Abs, due to combinatorial 
V(D)J gene segment variability of Abs’ heavy and light chains as well as Ab maturation, will show 
differences in their CDRs’ aa sequences, quaternary structure and consequently in antigen binding as 
well as epitope recognition. 
 
6.1 Antigenic domains of hCG 
There seems to be a finite number of antigenic domains on hCG and its subunits that are 
determined by its above mentioned structural properties. On the other hand the number of epitopes 
within antigenic domains can be large and ultimately corresponds to the theoretical Ab repertoire that 
can be generated [41]. The size of the antigen-specific repertoire varies with individual immune 
responses, haplotypes and species. Thus there will be significant variation in the numbers of epitopes 
corresponding to particular amino acid combinations within given antigenic domains recognized by 
Abs of different species and individuals [41].  
Thus even when interacting with and spatially covering very similar antigenic surfaces different 
Abs will display different binding energy of their Ag binding site with certain aa within the set of the up 
to 15 amino acids constituting an epitope [55] and in particular with a small number of  aa residues 
providing essential binding energy. As an example, the major antigenic domain on the tips of βŁ1+3 
encompassing aa hCGβ20-25+64+68-81 [7, 42, 43, 56] corresponds very well to the sizes of 
discontinuous epitopes and is recognized by large numbers of Abs that show substantial variability in 
recognition of a few essential contact aa even though they cover more or less the same surface with 
its cylinder-shaped paratopes (Figure 3.) [41, 48].  
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Prominent antigenic domains of hCG are defined by structures bulging out from the molecule 
such as βck residues Arg10 and Gln89 (epitope β1), aa residues α13-22 on αŁ1 whereby three 
hydrophobic aa Pro16, Phe17, Phe18 and and presumably nearby αMet71 and αPhe74 on αŁ3 play 
pivotal roles for epitopes α1, α2, and α4, and aa residues β20-25+64+68-81 on βŁ1+3, encompass 
epitopes β2 - β6 and analogous epitopes [7, 42, 56]. The latter region is located on the two neighboring 
loops βŁ1 and βŁ3, each between two reverse running β-sheets, with no particular secondary 
structure, but stabilized by an additional disulfide bridge between Cys23 and Cys72. Such prominent 
bulges make good epitopes as observed in other proteins [51] and can act as antigenic domains 
independent of the immunized species [41, 45].  
 
6.2 Spatial requirements of epitopes 
hCG not considering its hCGβCTP is shaped like a “banana” (75 Å × 35 Å × 30 Å, diameters) [11, 
57]. Its solvent accessible surface area is calculated by effectively rolling a probe sphere over the 
coordinates and amounts to 11,500 Å2 for hCG without its CTP and its carbohydrates and around 
16,000Å2 including the CTP but without carbohydrates. Not all of its surface fulfills the criteria for Ab 
binding such as bulging structures and steric accessibility as e.g. the beginning of hCGβŁ1+3 are 
blocked by bulky self-associated carbohydrate branches N-linked to Asn13 and 30 which are close to 
the hCG N-linked Asn52 antennae [11]. Thus N-linked carbohydrate antennae of hCG are not 
immunogenic per se but might shield some parts of the protein backbone from being recognized by 
Abs having an assumed footprint of the same size as an epitope of 1,000 Å2 (Fig.3) [7, 36, 58]. 
Moreover some regions might be immunologically inert as no T-cell help is provided or due to gaps in 
the Ab specificity repertoire. Thus the surface theoretically suitable for binding of Abs might be in the 
order of 7,500 Å2. Total binding surfaces of two cylinder-shaped anti-hCGα- and anti-hCGβ-Fabs were 
shown to be 734 Å2 and 855 Å2 in sizes. The corresponding antigenic solvent accessible surface 
areas covered by these Fabs were 780 Å2 for an α2/4 epitope located in antigenic domain αŁ1,3, which 
is primarily constituted of aa hCGα14-21+71+74, and 930 Å2 for a β2-5 epitope in antigenic domain 
βŁ1+3 (aa hCGβ20-24 + Arg68 + aa hCGβ73-81) [56].  
The major antigenic domains of hCG are located at either end of the hCG molecule at the tops of 
the neighboring Ł1+3 of either subunit (Fig. 2). As a consequence mAbs that interact with the 
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protruding loops exhibit canyon-like crevices in their binding sites as shown by co-crystallization of 
Fab(anti-α) – hCG - Fab(anti-β) ternary complexes [56]. 
hCG - neglecting its hCGβCTP - may harbor minimally five up to 7 antigenic domains [7, 42]. In 
fact Abs were shown to bind simultaneously to five epitopes β1 + β3 + α2 + α3 + c4 [45] reflecting five 
spatial independent antigenic domains ck + βŁ1+3 + αŁ1 + αŁ3 + c4. Two additional independent 
domains (β8 and β 9) are located on the βctp.  
 
6.3 Assembled vs. linear epitopes 
The majority of epitopes on hCG are arranged in structurally inherent antigenic domains that 
encompass continua of overlapping epitopes. It therefore is not possible to draw definite borders 
between them. Abs to hCG and related molecules preferentially bind to assembled i.e. composite, 
discontinuous epitopes determined by the tertiary and quaternary structure and rarely bind to linear 
continuous epitopes of the primary structure [59]. This is in agreement with findings for other antigens 
where more than 90% of Abs against native antigens recognize discontinuous epitopes [60]. 
Nevertheless, the boundary between discontinuous epitopes and stretches of aa residues is 
somewhat blurred since the former may contain short stretches of linear peptide segments of about 
five aa in length [51]. In hCG this e.g. is the case with overlapping epitopes α2 (aa hCGα13-18) and α4 
(hCGα17-22) on αŁ1. As these sequences are only recognized with affinities that are orders of 
magnitude lower than those for the full length proteins hCG or hCGα, they seem to represent only part 
of the epitope with a limited degree of similarity [56, 61].  
Only two epitope regions of hCG, epitope β9 (aa hCGβ113-116) and β8 (aa hCGβ135-145) on the 
hCGβCTP are unequivocally of linear appearance (for reviews see [7, 42, 43]). All other hCGβ and 
hCGβcf epitopes require conformational correct folding of the protein backbone as demonstrated with 
reduced and alcylated subunits and natural and synthetic peptides [59, 62] and with one exception 
(epitope β14 represented by a single mAb) map to the immunodominant region hCGβcf [7].  
 
6.4 hCGβCTP epitopes  
hCGβ-related epitopes not determined by hCGβcf, with one exception, are located on the 
hCGβCTP (aa hCGβ113-145) [59] (Fig. 2B). hCGβCTP is of low antigenicity as even in 
hyperimmunized animals few Abs of generally low affinity are elicited as compared to the remaining 
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part of the hCG molecule [42, 63]. The three-dimensional structure of hCGβCTP has not been resolved 
yet. hCGβCTP seems to be rather flexible “tail” with no defined secondary structures and is not 
constrained by any disulfide bridges [11]. As it has been incorporated into the coding sequence rather 
by chance it has no obvious function in receptor binding but hCG as compared to hLH has acquired 
prolonged metabolic half-life by its Ser-linked core-1 and 2 carbohydrate antennae [16, 17]. 
Nevertheless, hCGβCTP-mAbs by definition show high selectivity for hCG versus hLH and are used in 
various commercial sandwich type immunoassays where they show strong synergy in affinity with 
other β- and α-mAbs [64]. 
As mentioned above hCGβCTP located epitopes β8 (hCGβCTP135-145) and β9 (hCGβCTP113-
116) are determined by the primary structure i.e. are composed of linear aa sequences [7, 42, 59]. 
Polyclonal antisera against the hCG or hCGβCTP recognize preferentially domain β 8 and to a much 
lesser extent β9 [15]. The immunodominant region of hCGβCTP is located at its very carboxyl-terminal 
end encompassing aa residues hCGβCTP135-145 (antigenic domain β8.1-3).  
The aa residues providing essential binding energy for this domain were determined in great 
detail. The full β8.1 epitope consists of seven aa (hCGβCTP139-145: Asp139-Thr140-Pro141-Ile142-
Leu-143-Pro144-Gln145) with Asp139, Pro144 and Gln145 essentially involved in binding and 
representing the functional epitope [54], whereby Asp139 seems not to be directly recognized by Abs 
but rather contributes to correct spatial presentation of the target aa residues hCGβCTP143-145. Abs 
against this epitope bind with identical affinity to hCG, hCGβ, hCGβCTP109-145, hCGβCTP135-145 
and hCGβ139-145. Thus, this is a rare case where the native protein elicits Abs that recognizes a 
continuous peptide which represents the complete epitope (Figure 4).  
 
6.5 hCGβ loops 1+3 epitopes 
Antibodies against hCG recognize a limited number of dominant antigenic domains. Far more 
than hundred mAbs against the major antigenic domain βŁ1+3 were identified by the two “ISOBM 
Tissue Differentiation (TD)-7 Workshops (TD-7 WSs) on hCG and Related Molecules” and by other 
studies. Within that domain Abs recognize epitopes with different affinities and slightly different 
specificity profiles [7, 41, 42, 44, 45, 56, 65, 66] (Fig. 2B and C). Variability in aa recognition of 
epitopes β2 - β5 in this particular antigenic domain causes differences in Abs’ specificity, e.g. hLH 
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cross-reactivity, and generally in affinity of Abs [41]. Abs against epitopes β1, β2/β4 and β3/β5, 
respectively, display <0.1%, ≤1% and >10% cross-reactivity with hLH and hLHβ[7]. 
Contact amino acids were identified by mutational analyses of hCGβ, whereby special care was 
taken not to disturb the overall spatial conformation of the molecule: Pro24, Val25, Arg68, Gly71 and 
Gly75 were identified to be involved in epitope β3, residues Lys20, Glu21, Gln22, Gly75 and Asn77 in 
free hCGβ subunit epitope β6, and Arg68 in epitopes β2, β4 and β5 thereby forming functional epitopes 
[54]. By different techniques other laboratories confirmed βŁ1+3 as major antigenic domain with 
essential contact amino acids Lys20, Glu21, Gln22, Pro24 plus Arg68 and hCGβ73-81 [56, 65]. 
By definition, identical epitopes recognized by Abs within an antigenic domain only exist in the 
rare cases where genetically identical Abs are used. For reasons of simplicity, Abs with highly related 
but not identical features that recognize and cover very similar molecular surfaces, are defined to 
recognize the same epitope [7, 41].  
 
6.6 hCGβ cystine knot epitopes 
The second important antigenic domain of hCGβ is far less immunogenic, but diagnostically 
highly useful as it is distinct and not shared by hLH [7]. It is the only hCG/hCGβ-specific domain that is 
not located on the unique hCGβCTP, but centered around the ck and comprises epitopes β1 and β7 
with Arg10, Arg60, Asp61 and possibly Gln89 as contact aa residues [47, 48].  
 
6.7 hCGα and αβ epitopes 
As in assembled and free hCGβ, and hCGβ-derived variants where most Abs recognize domain 
βŁ1+3, the majority of hCGα-mAbs is directed against neighbouring beta-strand loops αŁ1 and αŁ3 
[43]. The antigenic surface of hCGα is composed of four antigenic domains [7, 61]:  
 
i. The immunodominant region on N-terminal loop αŁ1 encompasses amino acids hCGα13-22 
containing parts of epitopes α1, α2 (hCGα13-18) and α4 (hCGα17-22) [61]. This is in 
agreement with the results of other laboratories [56, 65, 67] and with the fact that there is an 
unusual bend at aa hCGα Asn15 resulting in Pro16, Phe17 and Phe18 bulging away from 
the antiparallel strand [11]. This structure together with nearby Met71 and Phe74 of loop αŁ3 
provides a prominent immunogenic surface [56],  
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ii. the region on αŁ3 around Tyr65/Arg67 that encompasses a large part of the accessible 
surface area contains epitopes α3/5 [43],  
iii. the sequence hCGα33-42 on the single opposing loop αŁ2 is important for subunit 
association [11] and thus specific for non-combined i.e. free hCGα (epitope α6) [61, 68] and  
iv. the very carboxyl-terminal end of hCGα contains epitope α7 (hCGα87-92) [61, 67, 69].  
 
Heterodimer specific epitopes are only present on hCG±hCGn. Abs against such epitopes are 
sterically incompatible with Abs recognizing hCGα epitopes on loop αŁ1 (α1, α2 and α4) [44, 45] and 
sensitive to nicking of between aa hCGβ44/45 and 47/48 in assembled βŁ2 [29, 70]. The X-ray 
structure show both regions to be in close proximity as the two subunits are associated in a head-to-
toe fashion [11]. 
 
6.8 Epitopes and carbohydrates 
Some molecular regions are immunologically inert and no Abs have been identified against them, 
due to lack of T-cell help, shielding by glycans or inaccessibility due to protein folding [41, 53]. All hCG 
epitopes, except for epitope β8.3 on hCGβCTP that consists of a core-2 type glycan attached to Ser132 
and surrounding peptide structure [71, 72] (Figs.1 and 2B), are determined by the protein backbone 
and consequently are present on asialo- and deglycosylated hCG [36, 58]. Moreover neither affinity of 
mAbs nor numbers of epitopes or spatial relationships of epitopes nor receptor or biological activity 
were severely compromised even in highly acidic and heavily glycosylated pregnancy and tumor 
isoforms [12, 36].  
The amino acids Asn13 and Asn30 of hCGβ carrying N-linked carbohydrate branches spatially 
are in proximity, are mutually associated and form a prominent bulky structure that is hydrophilic, thus 
surface exposed and therefore bulges away from the stem of β-sheet βŁ1. As no Abs bind to that 
molecular region these bi- or tri-antennary N-linked carbohydrates obviously render this region 
immunologically inert [7, 47, 48]. 
 
7. hCG methods 
Harmonization of antigenic domains and epitopes based on epitope maps and Ab specificity 
profiles is essential for reliable hCG measurements. The important features for reliable pregnancy 
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detection in urine seem to be adequate clinical and analytical sensitivity, specificity versus hLH/hLHβ 
(<1%) and, most importantly, it has to be assured that non-measured hLH and hCG variants such as 
hCGβcf do not interfere with signal. Detection has to reliably work irrespective of the high dynamics of 
absolute levels and relative hCG variant proportions, be it at the first few days of missed menses with 
an over-the-counter test or from few days to weeks of pregnancy with point-of-care tests. 
Pregnancy urine may contain as much as 2.7 ×106 pmol hCGβcf/L and 1 × 105 pmol hCG/L, 
whereby approximately three weeks from ovulation to term hCGβcf levels exceed those of hCG by up 
to ten fold [2, 75]; Upper reference limits for hCG, hCGβ and hCGβcf are ≥12 pmol/L in non-pregnant 
women [2]. In pregnancy serum hCGβcf is virtually absent and hCGβ levels are lower than 1% of hCG 
levels; This percentage increases in choriocarcinoma. 
Testicular cancer patients’ serum levels of hCG may even rise up to 1.4 × 107 pmol/L as 
compared to a normal range of <0.5–5 pmol/L in sera of normal men [81]. Non-trophoblastic cancers 
may predominantly produce hCGβ and 20–50% of these hCGβ only [2, 23, 82]. 
 
7.1 hCG detection by three categories of methods 
Qualitative hCG detection in serum and particular in urine is achieved by three categories of 
methods that reliably and robustly measure either hCG±hCGn only, preferably via mAbs directed 
against epitopes in domains αŁ1 - βŁ1+3 or c2/3 - βŁ1+3 (category I assays), or hCG+hCGβ+variants 
excluding hCGβcf by using epitopes β8 and β2 in antigenic domains βctp and βŁ1+3, respectively, 
(category ii assays with restricted pan-hCG/β recognition) or including hCGβcf by using epitopes β1 – 
β2 or β4 in antigenic domains βck - βŁ1+3, (category iii assays) providing broad pan-hCG/β and 
variants measurement [4, 73] (Fig. 5).  
Numerous other epitope combinations are theoretically feasible for hCG±hCGn detection in 
category (I) methods, each of which has its own advantages and drawbacks; thus ultimately no 
method can be advocated to be superior. Diagnostic first line category (iii) assays are constructed with 
pairs of mAbs directed against a βck related epitope (β1) combined with βŁ1+3 mAbs against epitopes 
β2 or β4 as used in the hCG+hCGβ+hCGβcf wide spectrum assay [41].  
For the qualitative detection of pregnancy in urine it generally makes no difference which of the 
three principle assay designs are used addressing either hCG-only or a restricted or broad range of 
pan hCG/β variants [73, 74]. All of these hCG-related surrogate markers rise in parallel at the 
  
- 15 -
beginning of pregnancy [75] and regardless of the assay scheme used (category i-iii)  pregnancies 
seem to be reliably detected. However in some extreme situations, presumably at the end of the  
1st trimester of pregnancy when hCG and variant levels are highest, some difficulties may arise for 
hCG-only (category i) and restricted pan hCG/β concepts (category ii) [39, 40, 76]. To avoid such 
reliability issues category (iii) βck – βŁ1+3 assay designs are preferable [4]. 
When hCG is quantified in urine antigenic determinants and specificity profiles of Abs have to be 
harmonized as large differences in results arise when other assay concepts than pan hCG/β/βcf via 
βck – βŁ1+3 antigenic determinants are used [4]. 
 
7.2 Method specificity and high-dose hook effects 
Possible impairment of signals in sandwich methods by non-measured variants like hCGβcf 
thereby causing high-dose hook effects is due to differences in the specificity profiles of the two Abs 
used, or generally due to an overload of the binding capacity of either Ab. When in a pregnancy test 
e.g. an anti-alpha Ab (epitope α4, antigenic domain αŁ1) is combined with an anti-hCGβ-mAb (e.g. 
epitope β1; antigenic domain βck) [39] it will specifically provide the desired signal for hCG plus hCGn 
but will be susceptible to signal inhibiting interferences with all hGPHs and its free α-subunits, due to 
the specificity profile of the α-mAb, and with all hCGβ variants, in particular hCGβcf, due to the mAb 
directed against epitope β1 (Fig.3).  
Even if the expected concentrations of interfering hGPHs were low, hCGβ variants like hCGβcf in 
urinary samples and hCGn and truncated hCG in standards [7] could still pose problems. Up to 
twenty-fold excess of hCGβcf may occur in second trimester pregnancy urine when hCG levels peak. 
hCGn recognition in itself will give rise to calibration problems if the 3rd or 4th IS for hCG were used 
that contain approximately 10% of it. To overcome hCG variant interference it is necessary to choose 
hCGβ-Ab pairs of identical variant recognition and thereby avoiding over-specificity of one of the two 
Abs and consequently potential interference in signal of important analytes like hCGβcf in urine. 
 
7.3 hCG variant selective methods 
For qualitative and quantitative “hCG” pregnancy tests no selective detection of hCG variants is 
necessary. Separate hCG and hCGβ measurements can be helpful to discern normal pregnancy from 
choriocarcinoma, for the diagnosis of testicular cancer and non-trophoblastic cancers when the either 
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the ratio of hCGβ to hCG or hCGβ itself is selectively increased. Specific assays for hCGβ in serum 
are also used for Down’s syndrome screening in the first trimester of pregnancy. Such assays again 
can be constructed with a mAb directed against a βck related epitope (β7) combined with the same 
anti-βŁ1+3 mAbs against epitopes β2 or β4 as in the hCG+hCGβ+variant wide spectrum assay  
(Table 2.) [41]. All assays for selective measurement of hCG, hCGβ, hCGβcf, hCG- and hCGβ-derived 
molecules involve a mAb directed against βŁ1+3 epitope β2 or β4 combined with the respective 
variant-specific mAb. 
In addition to the epitopes on holo-hCG, two epitopes are located on free hCGβ and hCGβcf (β6 
and β7) but not on hCG. One additional epitope (β14) is present on hCGβ only, four epitopes are 
specific for hCGβcf (β10 - β13), thus are not shared with hCGβ, hCG or hLH/hLHβ, and two (α6 and α7) 
are present on free hCGα only. MAbs against such epitopes are highly useful for variant-selective 
immunoassays designed to measure free hCGβ, hCGβcf or hCGα, respectively, in the presence of 
holo-hCG, other GPHs and hCG protein backbone variants (Table 2).  
 
8. Conclusion 
hCG and its molecular variants carry a limited number of antigenic domains that are structurally 
determined by bulging surfaces and protrusion indices. These antigenic domains provide the structural 
bases for overlapping epitopes that only acquire identity by complementary recognition through CDRs 
in Abs’ Fabs. Thus each genetically different Ab defines its own epitope. The elucidation of the 
molecular relationship of antigenic domains, epitopes and Ab specificity profiles are a crucial first step 
to harmonize Abs in diagnostic methods and thereby improve patient management. 
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 MAb and method specificities  
Analytical 
targets 
Code 
Epitopes 
Antigenic 
domain 
Molecular 
localization 
Specificity 
mAbs & assay 
Appropriate 
clinical use 
 
hCG+hCGβ 
+hCGβcf 
Category iii 
β1
 
βck β10+60+89 pan hCG/β Oncology, Down’s 
Early pregnancy 
OTC, POC, lab assay 
β2
a) 
βŁ1+3 β20-25+68-77 pan hCG/β 
β1 - β2
b)
 
βck - βŁ1+3  pan hCG/β 
 
hCG+hCGβ 
no hCGβcf! 
Category ii 
β8.1 βctp β141-44 hCGβCTP Oncology 
Early pregancy 
Prenatal Screen 
β2
b)
 
βŁ1+3 β20-25+68-77 pan hCG/β 
β8 - β2
b)
 
βctp–βŁ1+3  restr.panhCG/β 
 
 
hCG 
Category i 
c3
c)
 
βŁ2+αŁ1 β45-48+α13-22 hCG + hCGn Early pregnancy 
Oncology, Down’s 
(plus β detection) 
β2
b)
 
βŁ1+3 β20-25+68-77 pan hCG/β 
c3 - β 2
a)
 
βŁ2+αŁ1-βŁ1+3  hCG + hCGn 
 
 
hCGβ 
β7
 
βck β61+89 free hCGβ Oncology 
Prenatal Screen 
(plus hCG detection) 
β2
b) 
βŁ1+3 β20-25+68-77 pan hCGβ 
β7 - β2
c)
 
βck - βŁ1+3  hCGβ + βcf 
 
 
hCGβcf 
β11 hCGβcf hCGβcf hCGβcf Pregnancy, Down’s 
Oncology 
Clinical utility? 
β2
b) 
βŁ1+3 β20-25+68-77 pan hCG/β 
β11 - β2
c)
 
βcf - βŁ1+3  hCGβcf 
 
 
hCGα 
α6
 
αŁ2 α33-42 free GPHα Oncology 
(pituitary, testis) 
Clinical utility? 
α5
d) 
αŁ3 αTyr65+Met67 pan GPHα 
α6 - α5
c)
 
αŁ2 - αŁ3 
 free GPHα 
 
Table 2  
Key points of sandwich assays for hCG and/or hCG variants as recommended by the two ISOBM WS 
on measurement of hCG Modified with permission. [7, 41]: Over-the-counter, point-of-care and 
laboratory based hCG tests are constructed according to three epitope and specificity profile concepts: 
category (i) hCG-only measurements, category (ii) restricted pan hCG/β recognition (no hCGβcf) and 
category (iii) wide pan hCG/β specificity including hCGβcf. For first line hCG tests a pan hCG/β 
specificity profile was suggested that is best achieved by the use of pairs of mAbs against antigenic 
domains βck - βŁ1+3 whereby epitopes β1 – β2/4 are superior candidates (category iii tests) [4]. The 
popular category (ii) tests using the hCGβCTP as a target (combination of antigenic domains βctp - 
βŁ1+3; epitopes β8 – β2/4) are of restricted pan hCG/β + variant recognition recognition; it does not 
measure hCGβcf, that at high concentrations might induce a high-dose hook effect. The category (i) 
hCG-only method does not detect free subunits or hCG βcf but is prone to hook effects caused by 
both due to non-congruent specificity profiles of the two mAbs [39, 40, 76]. Many more epitope 
combinations are possible for the measurement of hCG-only [4] but no clear recommendation be 
given. The method for hCGβ (+hCGβcf + hCGβ-variants) is highly discriminative versus hCG and 
hCGn. hCGα and hCGβcf methods are highly specific for their target analytes but clinical utility of such 
assays is not established.  
a)
… alternatively a mAb directed against epitope β4 (domain βŁ1+3) can be used  
b)
… Sandwich method with mAbs directed against given epitopes 
c 
… alternatively a mAb directed against epitope c2 (domain βŁ2+αŁ1) can be used 
d) 
… alternatively a mAb directed against epitope α4 (domain αŁ1) can be used 
GPHα… glycoprotein hormone alpha subunit; hCGβ cystine knot … βck; loop … Ł 
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 Figure 1 
hCG protein backbone variants and isoforms 
A clear nomenclature describing protein backbone hCG variants has been put forward [6] and adopted 
by the “IFCC WG on Standardization of hCG Measurements” [8]: hCG is the bioactive intact αβ-
heterodimer (MW 36.3; 5th IS 75/364 and 1st IRR 99/688), nicked hCG (hCGn) is clipped between aa 
hCGα44/45 and 47/48, the hCGα-subunit (92 amino acids, MW 13.3; 1st IRR 99/720) is N-glycosylated 
at Asn52 and Asn78, hCGβ (aa hCGα1-145, MW 23.0; 1st IRR 99/650) contains two N-linked (Asn13 
and Asn30) and up to four O-linked (Ser121,127,132 and 138) carbohydrate units, nicked hCGβ 
(hCGβn) is clipped around aa hCGβ45-48 and hCGβ core fragment (hCGβcf, aa hCGβ6-40+β55-92, 
MW 9.8, isoelectric point 9.8!) retains the cystine knot and both adjacent loops 1+3 but has lost loop 2, 
the N-terminus and the hCGβCTP. Its N-linked carbohydrate branches are truncated to its Mannose 
cores [26]. Isoforms of hCG are differently terminally sialylated. Pregnancy hCGα and hCGβ-linked 
carbohydrates are of the bi-antennary type shown in black, whereas highly glycosylated malignancy 
associated hCGβ isoforms that show great variability are depicted in red. Large glycans seem to 
inhibit subunit association between free hCGβ and hCGα subunits. In pregnancy hCGβ Ser121 always 
contains a bi-antennary core-2 and Ser138 a core-1 carbohydrate structure with one or two sialic 
acids. Malignancy-derived hCGβ contains an increased proportion of O-linked core-2 type glycans 
[77]. The variant that is solely defined and detected by a single mAb (B152) directed against 
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hCGβCTP-located epitope β8.3 is recognized independently of additional glycosylation modifications in 
the remaining part of hCGβ and itself is subject to variability (encircled in red). Numbers represent 
positions of amino acid residues in the peptide chains. The disulfide bridges are depicted by S – S. 
 … GlcNAc, … Fuc,  … GalNAc,  … Man,  … Gal,  … NeuAc 
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Figure 2 
Epitope maps for hCGβ, hCGα and hCG.  
Models are based on the X-ray structures of hCG (PDB codes 1HRPand 1QFW). The carboxyl-
terminal peptide aa residues (hCGβ 111-145) have been modeled in an extended unstructured 
conformation with O-linked carbohydrates and the complete N-linked carbohydrates as extensions of 
the core carbohydrates visible within the crystal structures. The protein backbones are shown in a 
schematic form with β strands represented as arrows, hCGβ depicted in green and hCGα in blue, the 
disulphide bridges are shown in ball and stick coloured yellow. The extent of hCGβ-subunit 
carbohydrates are illustrated in space filling representation coloured in grey scale (black and blue 
fonts), and the protein solvent accessible surface as a transparent surface. Individual antigenic 
domains/epitopes are represented in discrete solid surface colours although there is likely to be 
significant overlap in adjacent epitopes.  This structural diagram and others were produced using the 
CCP4MG program [78]. 
As previously shown the majority of epitopes is located on heterodimeric hCG as well as the non-
assembled hCGα (epitopes α1 – α5) and hCGβ subunits (β1 – β5, β8/1-3β9) [59, 61]. Upon subunit 
dissociation free subunit epitopes become available (β6, β7, β14, α6, α7) whereas conformationally 
(c) determined epitopes (c1 – c4) defined by the quaternary intact structure disappear [11]. When 
hCGβ is metabolized to hCGβcf further epitopes emerge (β10 – β13) [7, 43] (not shown).  
(A) hCGβ antigenic domains βck, βŁ1+3, βctp and βŁ2. 
hCGβ-associated epitopes are arranged in four antigenic domains (i) the βck domain (aa hCGβ) (ii) 
the tips of the two nearby loops βŁ1+3 (hCGβ20-25+68-75, epitopes β1 - β6 plus hCGβ64,77-81 [56]). 
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The major antigenic structures of hCG, hCGβ and of its metabolic variants are defined by the aa 
sequences corresponding to hCGβcf [7], (iii) the βctp with linear epitopes at the very carboxyl-terminal 
(hCGβ135–145, epitope β8), the beginning of the CTP (hCGβ113–116, epitope β9) and two minor 
antigenic determinants in between (not shown) [59, 79] and (iv) the βŁ2 where αβ-heterodimer-specific 
c1 and c2 epitopes have a share on (hCGβ44-48) [8, 70]. The conclusions concerning molecular 
localization are just circumstantial as such c-type mAbs do not recognize uncombined hCGβ to a 
significant extent but are dependent on intact peptide bonds hCGβ44/45 and hCGβ47/48 [70]. 
In the hCGβ molecule the N-linked carbohydrate carrying amino acids Asn13 and Asn30 spatially are 
in proximity, mutually associated and form a prominent bulky structure that bulges from the stem of β-
sheet βŁ1. As no Abs bind to that molecular region the N-linked carbohydrate branches obviously 
render this region immunologically inert  [7, 47, 48]. 
The expression of hCGβ epitopes differs between hCG and variants which has impact on the 
specificity profiles of Abs. Abs against epitopes β1 - β5 are pan-hCG/β reagents, that recognize hCG, 
hCGn, hCGβ, hCGβn, hCGβcf and to various degrees hLH and hLHβ whereby in liquid phase titration 
and competitive immunoassays LH cross-reactivity of <0.1% is characteristic for mAbs against epitope 
β1, <1% for β2 and β4 and >>1% for β3 and β5. Other epitopes are present on particular variants only: 
(i) epitopes β6 and β7 on hCGβ, hCGβn and hCGβcf but not on αβ-heterodimers, (ii) βCTP-epitopes β8 
and β9 on hCG, hCGn, hCGβ, hCGβn and hCGβCTP but not on hCGβcf, (iii) epitopes β10 to β3 are 
specific for hCGβcf and neither shared by hCG nor any other hCG-related variant and (v) epitope β14 
is specific for hCGβ (not shown) [7, 41].  
(B) hCGα antigenic domains αŁ1 and 3, αŁ2 and αctp  
The antigenic surface of hCGα comprises 2 major and 2 minor antigenic domains [7, 61]. As in 
assembled and free hCGβ, most hCGα-mAbs are directed against the adjacent beta-strand loops 1 
and 3 [43]. Loop 1 is characterized by a protruding molecular structure around aa hCGα16-18 [11] that 
is part of the most important antigenic domain comprising amino acids hCGα13-22 [61] hosting part of 
epitopes α1, α2 (hCGα13-18) and α4 (hCGα17-22) [56, 61, 65, 67, 68] that is connected to hCGα71 & 
74 on loop 3 [56]. C-type epitopes on heterodimeric hCG and also on hFSH seem to be associated 
with these loop 1 sequences [45, 46]. The second immunodominant region of hCGαon loop 3 around 
Tyr65/Arg67 determines epitopes α3 and α5 [43]. The sequence hCGα33-41 on the single opposing 
loop 2 is important for subunit assembly, covered in the heterodimer and thus specific for free hCGα. It 
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is rarely recognized by mAbs (epitope α6) [61, 68] as is the very carboxyl-terminal end of hCGα 
(hCGα87-92, epitope α7) [67, 69].  
(C) Epitope map of hCG  
In the hCG αβ-heterodimer the free subunit specific epitopes β6, β7, α6 and α7 as well as hCGβcf-
specific epitopes β10 to β13 are cryptic and not accessible to the respective mAbs whereas c-type 
epitopes determined by the quaternary structure appear (epitopes c1 – c4). Some epitopes flow 
together to large antigenic superdomains in the αβ-heterodimer, e.g. epitopes α1/α2/α4 - c2/c1/c3 - β1 
corresponding to molecular regions αŁ1 – βŁ2 – βck. This is structurally conceivable as 
hCGαPhe17+18+74 are in close hydrophobic contact with hCGβVal44 and Leu45 [11], the peptide 
bond between which has to be intact for c1+2 epitopes.   
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Figure 3 
The major antigenic domain of hCGβ  
The most immunogenic domain of hCGβ is located at the top of beta loops 1+3 (βŁ1+3) corresponding 
to aa residues hCGβ20-25+64+68-81. It is striking that when molecular complexes of Fab and hCG 
are modeled true to scale it appears that the Fab’s binding site substantially covers the top of βŁ1+3 
like an umbrella. Thus the antigenic domain of βŁ1+3 encompassing the β2 to β6 epitope cluster plus 
epitopes defined by other laboratories looks small in comparison to the Fabs bound to it [43]. 
Moreover the two self-associated bulky N-linked hCGβ carbohydrates that cover the peptidic stem of 
βŁ1 prevent recognition of the respective amino acid structures by Abs [7, 47, 48]. Thus not much 
spatial range is available for the recognition of βŁ1+3 by the Fabs’ binding sites and spatial differences 
in location between epitopes within this antigenic domain are only subtle and are mostly based on 
variability of preferential recognition of certain aa within that region thereby providing a functional 
epitope even when the different Abs’ Fabs cover more or less the same molecular region.  
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 Figure 4 
hCGβ139-145, the truly linear epitope β8.1 on natural hCG 
This is the rare case where a truly linear epitope exist that is recognized by a number of monoclonal 
antibodies (mAbs) generated against the native full-length protein. In the two ISOBM WSs four mAbs 
[7, 41] plus mAb M34III (kindly provided by Roche, Penzberg, Germany) were directed against epitope 
β8.1. hCG, hCGβ, hCGβCTP109-145 and hCGβ139-145 (Asp-Thr-Pro-Ile-Leu-Pro-Gln) all are equally 
well recognized when compared on a molar basis in competitive RIA [7], whereas peptides shortened 
by only one amino acid on either end (hCGβ140-145 and hCGβ139-144, respectively) each lose 
affinities by two to three orders, thus indicating pivotal roles for amino acids Asp139 and Glu145. No 
involvement of carbohydrate antenna Ser138 in epitope β8.1 was observed! Five mAbs directed 
against the facet β8.2 of this antigenic domain recognize naturally glycosylated hCG 3 to 4 orders of 
magnitude better than synthetic hCGβ135-145 [7] indicating an involvement of carbohydrate antennae 
Ser132 and/or Ser138 as seems to be the case for epitope β8.3 as shown by mAb B152 [25].  
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 Figure 5 
Measurement of hCG and variants 
Models of Fab interactions with hCG, hCGβ and hCGα based on the X-ray structures of hCG and the 
hCG Fv complex (PDB codes 1HRP and 1QFW respectively) and also the CTP specific Fab [80] (PDB 
code 1SBS). The hCGα and βprotein backbones are shown in a schematic form with β strands 
represented as arrows (colored green and blue, respectively), the disulphide bridges are shown in ball 
and stick colored yellow. The antigenic domains involved in assay construction are depicted in red 
font. The extent of carbohydrates on the α and β subunits are illustrated in space filling representation 
colored in grey scale, and the protein solvent accessible surface as a transparent surface.  Individual 
antigenic domains/epitopes are represented in discrete solid surface colors. The Fab structures were 
modeled from the Fv fragments in structure 1QFW [56] are represented in a schematic form with β 
strands represented as arrows and the individual immunoglobulin folded domains as transparent light 
yellow ellipsoids. This structural diagram and others were produced using the CCP4MG program [78]. 
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Over-the-counter, point-of-care and laboratory based pregnancy tests are constructed according to 
three epitope and specificity profile concepts: (a) Category (i) assays for hCG-only measurement: 
epitope pairing α4 - β2, the α4 epitope highlighted in red, the β2 epitope in dark blue. (b) Category (ii) 
assays for restricted panhCG/β measurement (no recognition of hCGβcf and CTP-truncated hCG and 
hCGβ variants): β8.1 - β2, the β2 epitope highlighted in dark blue, the β8.1 epitope in cyan. (c) Category 
(iii) assays for panhCG/β measurement: epitope combinations β1 - β2, the β1 epitope highlighted in red, 
the β2 epitope in dark blue. From all combinations shown, exclusively the category (iii) pairing of 
epitopes β1 – β2/4 will fulfill the criteria of a multipurpose method measuring a wide range of hCG and 
hCGβ and variants including hCGβcf, showing no hLH cross-reactivity and not even a theoretical 
possibility of interferences in signal such as high-dose hooking of non-measured metabolic variants 
like hCGβcf.  
Many more epitope combinations for hCG and hCG variant measurement are possible but only such 
combinations have been selected that per se will not cross-react with hLH or hLH derivatives. All other 
epitope combinations due to non-congruence of specificity profiles of the respective Ab pairs might be 
susceptible to such interferences [39, 40]. 
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